639 related articles for article (PubMed ID: 19293564)
21. [Topical immune modulation and risk of cancer].
Deleuran M; Zachariae C; Thestrup-Pedersen K
Ugeskr Laeger; 2009 Aug; 171(35):2468-71. PubMed ID: 19732533
[TBL] [Abstract][Full Text] [Related]
22. The role of pimecrolimus cream 1% (Elidel)) in managing adult atopic eczema.
Meurer M; Lubbe J; Kapp A; Schneider D
Dermatology; 2007; 215 Suppl 1():18-26. PubMed ID: 18174690
[TBL] [Abstract][Full Text] [Related]
23. Treatment of paediatric atopic dermatitis with pimecrolimus (Elidel, SDZ ASM 981): impact on quality of life and health-related quality of life.
McKenna SP; Whalley D; de Prost Y; Staab D; Huels J; Paul CF; van Assche D
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):248-54. PubMed ID: 16503881
[TBL] [Abstract][Full Text] [Related]
24. Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis.
Arellano FM; Wentworth CE; Arana A; Fernández C; Paul CF
J Invest Dermatol; 2007 Apr; 127(4):808-16. PubMed ID: 17096020
[TBL] [Abstract][Full Text] [Related]
25. A single-center open-label long-term comparison of tacrolimus ointment and topical corticosteroids for treatment of atopic dermatitis.
Neumann E; Amtage D; Bruckner-Tuderman L; Mockenhaupt M
J Dtsch Dermatol Ges; 2008 Jul; 6(7):548-53. PubMed ID: 18248495
[TBL] [Abstract][Full Text] [Related]
26. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
27. [Calcineurin inhibitors in treatment of atopic dermatitis. Topical corticoids now only in severe outbreaks? ].
MMW Fortschr Med; 2003 Jul; 145(29-30):62. PubMed ID: 12958787
[No Abstract] [Full Text] [Related]
28. Effect of pimecrolimus cream 1% on the long-term course of pediatric atopic dermatitis.
Papp K; Staab D; Harper J; Potter P; Puig L; Ortonne JP; Molloy S; Barbier N; Paul C;
Int J Dermatol; 2004 Dec; 43(12):978-83. PubMed ID: 15569038
[TBL] [Abstract][Full Text] [Related]
29. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
Hebert AA
Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
[TBL] [Abstract][Full Text] [Related]
30. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
[TBL] [Abstract][Full Text] [Related]
31. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
Kapoor R; Hoffstad O; Bilker W; Margolis DJ
Pediatr Dermatol; 2009; 26(6):682-7. PubMed ID: 20199441
[TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of topical calcineurin inhibitors in adult patients with atopic dermatitis.
Frankel HC; Qureshi AA
Am J Clin Dermatol; 2012 Apr; 13(2):113-23. PubMed ID: 22263704
[TBL] [Abstract][Full Text] [Related]
33. Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.
Hoetzenecker W; Ecker R; Kopp T; Stuetz A; Stingl G; Elbe-Bürger A
J Allergy Clin Immunol; 2005 Jun; 115(6):1276-83. PubMed ID: 15940147
[TBL] [Abstract][Full Text] [Related]
34. Production and clearance of cyclobutane dipyrimidine dimers in UV-irradiated skin pretreated with 1% pimecrolimus or 0.1% triamcinolone acetonide creams in normal and atopic patients.
Doelker L; Tran C; Gkomouzas A; Grand D; Sorg O; Saurat JH; Lübbe J
Exp Dermatol; 2006 May; 15(5):342-6. PubMed ID: 16630073
[TBL] [Abstract][Full Text] [Related]
35. Association Between Malignancy and Topical Use of Pimecrolimus.
Margolis DJ; Abuabara K; Hoffstad OJ; Wan J; Raimondo D; Bilker WB
JAMA Dermatol; 2015 Jun; 151(6):594-9. PubMed ID: 25692459
[TBL] [Abstract][Full Text] [Related]
36. The use of topical calcineurin inhibitors in lupus erythematosus: an overview.
Wollina U; Hansel G
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):1-6. PubMed ID: 18005117
[TBL] [Abstract][Full Text] [Related]
37. StabiEL: stabilization of skin condition with Elidel--a patients' satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid.
Gollnick H; Luger T; Freytag S; Bräutigam M;
J Eur Acad Dermatol Venereol; 2008 Nov; 22(11):1319-25. PubMed ID: 18540990
[TBL] [Abstract][Full Text] [Related]
38. Safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Munzenberger PJ; Montejo JM
Pharmacotherapy; 2007 Jul; 27(7):1020-8. PubMed ID: 17594208
[TBL] [Abstract][Full Text] [Related]
39. Long-term management of facial atopic eczema with pimecrolimus cream 1% in paediatric patients with mild to moderate disease.
Zuberbier T; Bräutigam M
J Eur Acad Dermatol Venereol; 2008 Jun; 22(6):718-21. PubMed ID: 18312323
[TBL] [Abstract][Full Text] [Related]
40. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
